中国经导管主动脉瓣置换术临床路径专家共识(2024版)  

2024 Expert Consensus on Clinical Pathway for Transcatheter Aortic Valve Replacement in China

作　　者：中国医师协会心血管内科医师分会结构性心脏病学组 亚太结构性心脏病俱乐部 宋光远 潘文志[3] 周达新[3] 吴永健 刘新民[2] 王墨扬 Structural Cardiology Committee of Cardiovascular Physicians Branch,Chinese Medical Doctor Association;Asia Pacific Structural Heart Disease Club;SONG Guangyuan;PAN Wenzhi;ZHOU Daxin;WU Yongjian

机构地区：[1]不详 [2]首都医科大学附属北京安贞医院 [3]复旦大学附属中山医院 [4]中国医学科学院阜外医院

出　　处：《中国循环杂志》2024年第11期1041-1057,共17页Chinese Circulation Journal

基　　金：国家重点研发计划(2020YFC2008100);首都临床特色诊疗技术研究及转化应用项目(Z221100007422117)。

摘　　要：经导管主动脉瓣置换术(TAVR)已经日臻成熟,2017~2023年期间我国开展中心数量由不到10家增加至600余家,每年置入量由数百例增加至超过10000例,TAVR在我国已进入持续稳定发展阶段。《中国经导管主动脉瓣置换术临床路径专家共识》2018版及2021版在我国TAVR快速发展的黄金时期发挥了重要指导作用。随着TAVR领域在循证证据、应用经验、指南更新、器械研发、术式改良等方面的进展,尤其是中国原创技术及治疗方案优化等方面陆续取得重要突破,特更新旧版临床路径专家共识。新版临床路径专家共识对TAVR患者术前临床评价、围术期影像学评估、规范化手术流程、围术期综合管理及术后康复随访等方面进行了详尽阐述,以进一步助力我国TAVR技术健康、规范发展,促进围绕该技术的临床和研究能力的稳定提升。Transcatheter aortic valve replacement(TAVR)has reached maturity and has entered a stage of steady and stable development in China.From 2017 to 2023,the number of centers conducting TAVR in China has increased from less than 10 to over 600,and the annual implantation volume has increased from hundreds to over 10000.The 2018 and 2021 editions of the"Expert Consensus on Clinical Pathway for Transcatheter Aortic Valve Replacement in China"played a crucial guiding role during the golden period of TAVR development in China.With significant progress in evidence-based practice,clinical experience,guideline updates,device development,and procedure technique improvements in the TAVR field,especially the important advances in technologies developed from China,protocol optimization based on Chinese clinical practices,it is necessary to update the previous clinical pathway consensus.The new version of the clinical pathway expert consensus has updated the standard procedures for preoperative clinical assessment,perioperative imaging evaluation,standardized procedural processes,comprehensive perioperative management,and postoperative rehabilitation follow-up for TAVR patients.This update aims to further promote the healthy and standardized development of TAVR technology in China and to steadily enhance the medical and scientific research capabilities with this therapeutic technology.

关 键 词：经导管主动脉瓣置换术 临床评估 影像学评估 规范化手术流程 围术期管理 

分 类 号：R54[医药卫生—心血管疾病]